147 related articles for article (PubMed ID: 20417865)
1. Concomitant loss of heterozygosity at the BRCA1 and FHIT genes as a prognostic factor in sporadic breast cancer.
Silva Soares EW; de Lima Santos SC; Bueno AG; Cavalli IJ; Cavalli LR; Fouto Matias JE; de Souza Fonseca Ribeiro EM
Cancer Genet Cytogenet; 2010 May; 199(1):24-30. PubMed ID: 20417865
[TBL] [Abstract][Full Text] [Related]
2. Alterations of the FHIT gene in breast cancer: association with tumor progression and patient survival.
Ingvarsson S; Sigbjornsdottir BI; Huiping C; Jonasson JG; Agnarsson BA
Cancer Detect Prev; 2001; 25(3):292-8. PubMed ID: 11425271
[TBL] [Abstract][Full Text] [Related]
3. Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations.
Gonzalez R; Silva JM; Dominguez G; Garcia JM; Martinez G; Vargas J; Provencio M; España P; Bonilla F
Br J Cancer; 1999 Oct; 81(3):503-9. PubMed ID: 10507777
[TBL] [Abstract][Full Text] [Related]
4. Loss of heterozygosity at BRCA1 locus is significantly associated with aggressiveness and poor prognosis in breast cancer.
Okada S; Tokunaga E; Kitao H; Akiyoshi S; Yamashita N; Saeki H; Oki E; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 May; 19(5):1499-507. PubMed ID: 22179631
[TBL] [Abstract][Full Text] [Related]
5. Allelic loss at the 8p22 region as a prognostic factor in large and estrogen receptor negative breast carcinomas.
Utada Y; Haga S; Kajiwara T; Kasumi F; Sakamoto G; Nakamura Y; Emi M
Cancer; 2000 Mar; 88(6):1410-6. PubMed ID: 10717624
[TBL] [Abstract][Full Text] [Related]
6. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas.
Ingvarsson S; Agnarsson BA; Sigbjornsdottir BI; Kononen J; Kallioniemi OP; Barkardottir RB; Kovatich AJ; Schwarting R; Hauck WW; Huebner K; McCue PA
Cancer Res; 1999 Jun; 59(11):2682-9. PubMed ID: 10363992
[TBL] [Abstract][Full Text] [Related]
7. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
[TBL] [Abstract][Full Text] [Related]
8. Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from hngh-risk patients.
Isaacs C; Cavalli LR; Cohen Y; Pennanen M; Shankar LK; Freedman M; Singh B; Liu M; Gallagher A; Rone JD; Dickson RB; Sidransky D; Haddad BR
Breast Cancer Res Treat; 2004 Mar; 84(2):99-105. PubMed ID: 14999140
[TBL] [Abstract][Full Text] [Related]
9. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers.
Arun B; Kilic G; Yen C; Foster B; Yardley DA; Gaynor R; Ashfaq R
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1681-5. PubMed ID: 16030101
[TBL] [Abstract][Full Text] [Related]
10. Frequent FHIT gene loss of heterozygosity in human papillomavirus-infected non-smoking female lung cancer in Taiwan.
Wang J; Cheng YW; Wu DW; Chen JT; Chen CY; Chou MC; Lee H
Cancer Lett; 2006 Apr; 235(1):18-25. PubMed ID: 15935551
[TBL] [Abstract][Full Text] [Related]
11. FHIT gene in gastric cancer: association with tumour progression and prognosis.
Noguchi T; Müller W; Wirtz HC; Willers R; Gabbert HE
J Pathol; 1999 Aug; 188(4):378-81. PubMed ID: 10440747
[TBL] [Abstract][Full Text] [Related]
12. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer.
Burke L; Khan MA; Freedman AN; Gemma A; Rusin M; Guinee DG; Bennett WP; Caporaso NE; Fleming MV; Travis WD; Colby TV; Trastek V; Pairolero PC; Tazelaar HD; Midthun DE; Liotta LA; Harris CC
Cancer Res; 1998 Jun; 58(12):2533-6. PubMed ID: 9635574
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity of the BRCA1 and FHIT genes in patients with sporadic breast cancer from Southern Brazil.
Santos SC; Cavalli LR; Cavalli IJ; Lima RS; Haddad BR; Ribeiro EM
J Clin Pathol; 2004 Apr; 57(4):374-7. PubMed ID: 15047740
[TBL] [Abstract][Full Text] [Related]
14. FHIT gene and flanking region on chromosome 3p are subjected to extensive allelic loss in Egyptian breast cancer patients.
Ismail HM; Medhat AM; Karim AM; Zakhary NI
Mol Carcinog; 2011 Aug; 50(8):625-34. PubMed ID: 21557333
[TBL] [Abstract][Full Text] [Related]
15. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P
Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851
[TBL] [Abstract][Full Text] [Related]
16. Loss of heterozygosity at the BRCA1 locus in Tunisian women with sporadic breast cancer.
Charef-Hamza S; Trimeche M; Ziadi S; Amara K; Gaddas N; Mokni M; Sriha B; Yacoubi T; Korbi S
Cancer Lett; 2005 Jun; 224(2):185-91. PubMed ID: 15914269
[TBL] [Abstract][Full Text] [Related]
17. Novel somatic mutations in the BRCA1 gene in sporadic breast tumors.
Janatova M; Zikan M; Dundr P; Matous B; Pohlreich P
Hum Mutat; 2005 Mar; 25(3):319. PubMed ID: 15712267
[TBL] [Abstract][Full Text] [Related]
18. Deletions of BRCA1/2 and p53 R248W gain-of-function mutation suggest impaired homologous recombination repair in fragile histidine triad-negative sebaceous gland carcinomas.
Becker K; Goldberg M; Helmbold P; Holbach LM; Loeffler KU; Ballhausen WG
Br J Dermatol; 2008 Dec; 159(6):1282-9. PubMed ID: 18717684
[TBL] [Abstract][Full Text] [Related]
19. Loss of BRCA2 correlates with reduced long-term survival of sporadic breast cancer patients.
Hampl JA; Hampl M; Reiss G; Koch R; Saeger HD; Schackert HK
Anticancer Res; 2004; 24(1):281-90. PubMed ID: 15015609
[TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer.
Cavalli LR; Singh B; Isaacs C; Dickson RB; Haddad BR
Cancer Genet Cytogenet; 2004 Feb; 149(1):38-43. PubMed ID: 15104281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
